A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

Inclusion Criteria:

• Have a diagnosis of psoriatic arthritis (PsA) for greater than or equal to (>=) 6months prior to the first administration of study intervention and meetClassification criteria for PsA (CASPAR) criteria at screening

• Have active PsA as defined by having at least 3 swollen joints and at least 3 tenderjoints at screening and at baseline

• Have at least 1 of the following PsA subsets: distal interphalangeal jointinvolvement, polyarticular arthritis with absence of rheumatoid nodules, arthritismutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis

• Have active plaque psoriasis, with at least one psoriatic plaque of >=2 centimeter (cm) diameter or nail changes consistent with psoriasis

• Have an inadequate response (IR) to anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy, defined as presence of active PsA despite treatment witheither 1 or 2 prior anti-TNF-alpha agent(s) and the following: a. Lack of benefit toeither 1 or 2 prior anti-TNF-alpha therapies, as documented in the participanthistory by the treating physician, after at least 12 weeks of etanercept,adalimumab, or certolizumab pegol therapy, or at least 14-weeks of infliximab, orany biosimilar of these 4 therapies. Documented lack of benefit may includeinadequate improvement in joint counts, physical function, or disease activity; b.The last dose of anti-TNF-alpha therapy must have occurred greater than 5 half-livesof the drug prior to first study intervention administration (washout period)

Exclusion Criteria:

• Has other inflammatory diseases that might confound the evaluations of benefit ofguselkumab and/or golimumab therapy, including but not limited to rheumatoidarthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr AxSpA), systemic lupus erythematosus, or lyme disease

• Has known intolerance or hypersensitivity to any biologic medication, or knownallergies or clinically significant reactions to murine, chimeric, or humanproteins, monoclonal antibodies (mAb), or antibody fragments

• Has received prior treatment with golimumab or guselkumab or has documentedintolerance to prior anti-TNF-alpha therapy in the participant history by thetreating physician

• Has received more than 2 prior anti-TNF-alpha agents (or biosimilars)

• Positive human immunodeficiency virus (HIV) antibody test